ScaleUp Bio announces Fusionopolis Ventures joining ADM as shareholder

ScaleUp Bio Pte. Ltd. (“ScaleUp Bio”) today announced that Fusionopolis Ventures Pte. Ltd. (“FVPL”), a subsidiary of Economic Development Innovations Singapore Pte. Ltd. (“EDIS”), will join ADM as a shareholder in ScaleUp Bio, supporting the company’s next phase of growth as a precision fermentation contract development and manufacturing organisation (CDMO) in Asia. FVPL is committed to building a leading biomanufacturing platform in Asia, supporting high-quality jobs and capability development, and partnering with industrial leaders to strengthen execution and market access.

As Singapore’s first and largest precision fermentation CDMO, ScaleUp Bio supports innovators in scaling from development through pilot and into commercial production. With its commercial pilot facility jointly operated with A*STAR Singapore Institute of Food and Biotechnology Innovation (SIFBI), and industrial capabilities now consolidated in Tuas, ScaleUp Bio is strengthening its position as a world-class CDMO focused on high-value bio-based specialty molecules across the cosmetics, pharmaceutical, energy, specialty chemical, food and nutrition sectors.

This integrated operating footprint enables a more seamless path from process development through scale- up and manufacturing, helping customers bring precision fermentation products to market more efficiently. In doing so, ScaleUp Bio addresses a critical infrastructure gap for companies seeking high-quality fermentation capacity to support commercialisation.

ScaleUp Bio’s customers can expect continuity of operations from its licensed and certified Singapore facility, further strengthened by fresh capital, aligned strategic backing and a sharpened focus on execution. This next phase enhances the company’s ability to serve customers as an integrated platform, helping reduce execution complexity, accelerate timelines and support more confident commercial scale-up.

(From left) Director of EDIS Abel Ang, Chairman of EDIS Philip Yeo, President, Asia Pacific (APAC) of ADM Fabiana Bianchi and M&A and Business Development Director, Asia Pacific at ADM Alberto Parisi.

Philip Yeo, Chairman, EDIS said: “This investment reflects our conviction in platforms that combine deep technical capability with disciplined scale-up execution. ScaleUp Bio’s CDMO platform in Singapore offers a strategic launchpad, with its regulatory strength and manufacturing ecosystem. In the same way that Singapore has become a manufacturing hub for biopharmaceuticals, I see this as the beginning of a broader regional platform designed to serve the growing biomanufacturing needs of Asia and beyond in precision fermentation.”

Fabiana Bianchi, President of Asia-Pacific, ADM said: “Precision fermentation is opening new opportunities to produce bio-based ingredients and solutions efficiently and at scale. Our continued partnership with ScaleUp Bio reflects ADM’s commitment to bringing these innovations to market across a growing range of industries.”

Aaron Yeo, General Manager, ScaleUp Bio said: “With FVPL’s support, ScaleUp Bio will sharpen our focus as a world-class CDMO for high-value bio-based specialty molecules. With our pilot and industrial capabilities now consolidated into a single operating footprint in Singapore, we can provide a more seamless and efficient path from process development through scale-up and manufacturing. This strengthens our ability to support innovators across multiple industrial applications.”